![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Mosunetuzumab + Polatuzumab Promising Trial Results for R/R LBCL
How effective is the bispecific antibody mosunetuzumab (Lunsumio, Genentech) when combined with the antibody-drug conjugate polatuzumab vedotin (Polivy, Genentech) for people with relapsed/refractory large B-cell lymphoma (LBCL)?
Comparing this treatment combination against the current LBCL standard of rituximab (Rituxan, Genentech) with polatuzumab supports improving standard care with more effective options.
At the 2024 ASH conference, Julio Chavez, MD, MS, from Moffitt Cancer Center, presented results from a phase 2 clinical trial on this promising combination. Listen to Dr. Chavez’s interview or read the research summary below to learn more.
Polatuzumab + Mosunetuzumab or Rituximab Results
The study is ongoing; however, so far, 80 people with relapsed/refractory LBCL have received polatuzumab with either mosunetuzumab or rituximab in eight 21-day treatment cycles.
Mosunetuzumab was given as an injection, while polatuzumab and rituximab were administered through IV infusions. Patients had the option to receive treatment in an outpatient setting, allowing them to go home afterward without needing an overnight hospital stay.
| Patients who received mosunetuzumab + polatuzumab | Patients who received rituximab + polatuzumab | |
| Overall response rate (percentage of patients who experienced a partial or full reduction of cancer cells following treatment) | 78% | 50% |
| Complete response rate (percentage of patients in which cancer was not detected by testing after treatment) | 58% | 35% |
| Average duration of response (how long remission lasted since achieving a response) | Not reached, meaning on average, patients were still in remission at the 18-month check-in after responding to treatment | 10.1 months |
| Average overall survival (amount of time patients were alive since the start of treatment) | Not reached, meaning on average, patients were alive at the check-in point of 18 months since starting treatment | Not reached, meaning on average, patients were alive at the check-in point of 18 months since starting treatment |
| Common side effects experienced by ≥30% of patients | Injection-site reaction (55%), diarrhea (48%), fatigue (35%), and constipation (30%) | Nausea (36%), diarrhea (33%), and fatigue (33%) |
| Percentage of patients who experienced serious side effects | 33% of patients, most commonly neutropenia | 26% of patients, most commonly neutropenia |
If you have concerns regarding how side effects can be managed with supportive care, please speak with your LBCL specialist.
Key Takeaways
A fixed-duration treatment of mosunetuzumab and polatuzumab, given in an outpatient setting, has shown greater effectiveness than rituximab and polatuzumab for people with relapsed/refractory large B-cell lymphoma (R/R LBCL), leading to higher response rates, longer remission, and manageable side effects.
This combination is currently being evaluated in phase 3 of the SUNMO study, and we look forward to further research as it continues to show promise as an effective treatment option for those in need of additional therapies.
Continue learning from experts about how bispecific antibodies are changing the LBCL treatment landscape
Watch Bispecific Antibodies for LBCL Event Recording
Sources:
- A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas
How effective is the bispecific antibody mosunetuzumab (Lunsumio, Genentech) when combined with the antibody-drug conjugate polatuzumab vedotin (Polivy, Genentech) for people with relapsed/refractory large B-cell lymphoma (LBCL)?
Comparing this treatment combination against the current LBCL standard of rituximab (Rituxan, Genentech) with polatuzumab supports improving standard care with more effective options.
At the 2024 ASH conference, Julio Chavez, MD, MS, from Moffitt Cancer Center, presented results from a phase 2 clinical trial on this promising combination. Listen to Dr. Chavez’s interview or read the research summary below to learn more.
Polatuzumab + Mosunetuzumab or Rituximab Results
The study is ongoing; however, so far, 80 people with relapsed/refractory LBCL have received polatuzumab with either mosunetuzumab or rituximab in eight 21-day treatment cycles.
Mosunetuzumab was given as an injection, while polatuzumab and rituximab were administered through IV infusions. Patients had the option to receive treatment in an outpatient setting, allowing them to go home afterward without needing an overnight hospital stay.
| Patients who received mosunetuzumab + polatuzumab | Patients who received rituximab + polatuzumab | |
| Overall response rate (percentage of patients who experienced a partial or full reduction of cancer cells following treatment) | 78% | 50% |
| Complete response rate (percentage of patients in which cancer was not detected by testing after treatment) | 58% | 35% |
| Average duration of response (how long remission lasted since achieving a response) | Not reached, meaning on average, patients were still in remission at the 18-month check-in after responding to treatment | 10.1 months |
| Average overall survival (amount of time patients were alive since the start of treatment) | Not reached, meaning on average, patients were alive at the check-in point of 18 months since starting treatment | Not reached, meaning on average, patients were alive at the check-in point of 18 months since starting treatment |
| Common side effects experienced by ≥30% of patients | Injection-site reaction (55%), diarrhea (48%), fatigue (35%), and constipation (30%) | Nausea (36%), diarrhea (33%), and fatigue (33%) |
| Percentage of patients who experienced serious side effects | 33% of patients, most commonly neutropenia | 26% of patients, most commonly neutropenia |
If you have concerns regarding how side effects can be managed with supportive care, please speak with your LBCL specialist.
Key Takeaways
A fixed-duration treatment of mosunetuzumab and polatuzumab, given in an outpatient setting, has shown greater effectiveness than rituximab and polatuzumab for people with relapsed/refractory large B-cell lymphoma (R/R LBCL), leading to higher response rates, longer remission, and manageable side effects.
This combination is currently being evaluated in phase 3 of the SUNMO study, and we look forward to further research as it continues to show promise as an effective treatment option for those in need of additional therapies.
Continue learning from experts about how bispecific antibodies are changing the LBCL treatment landscape
Watch Bispecific Antibodies for LBCL Event Recording
Sources:
- A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
- 627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas
about the author
Megan Heaps
Megan joined HealthTree in 2022. She enjoys helping patients and their care partners understand the various aspects of the cancer. This understanding enables them to better advocate for themselves and improve their treatment outcomes.
More on Treatment Advances
Get the Latest B-Cell Lymphoma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2025 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811